Diamyd Medical’s major owners fully subscribe for their share of a rights issue

Not for release, publication or distribution, directly or indirectly, in the United States, Canada, Australia, Hong Kong, Japan, New Zealand, Singapore, Switzerland, Singapore or South Africa. Diamyd Medical (NASDAQ Stockholm First North, DMYD B), world leader in the development of Antigen Based Therapy for type 1 diabetes, announced today that its major owners, Bertil Lindkvist and Anders Essen-Möller, notified that they will take up their share corresponding to approximately one third of the upcoming rights issue of SEK 22.1 million.Diamyd Medical’s rights issue is implemented with the